









市場行情
/
股票
/
nasdaq-crmd
/

CorMedix Inc

CRMD

7.145USD

+0.055+0.78%

交易中（美東）報價延遲15分鐘

559.80M總市值

3.01本益比TTM



CorMedix Inc

7.145

+0.055+0.78%

概覽公司財務分析

概覽

公司

財務

分析

關於 CorMedix Inc 公司

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

CorMedix Inc簡介



公司代碼CRMD

公司名稱CorMedix Inc

上市日期Mar 25, 2010

CEOTodisco (Joseph)

員工數量64

證券類型Ordinary Share

年結日Mar 25

公司地址300 Connell Drive

城市BERKELEY HEIGHTS

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編07922

電話19085179500

網址https://cormedix.com/

公司代碼CRMD

上市日期Mar 25, 2010

CEOTodisco (Joseph)

CorMedix Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Joseph (Joe) Todisco

Chief Executive Officer, Director

302.20K

Mr. Steven W. Lefkowitz

Independent Director

87.65K

-40000.00%

Ms. Susan Blum

Chief Financial Officer

69.69K

+69686.00%

Ms. Janet M. Dillione

Independent Director

23.47K

Mr. Gregory Scott (Greg) Duncan

Independent Director

13.33K

+13333.00%

Mr. Robert Stewart

Independent Director

11.00K

Mr. Myron M. Kaplan, J.D.

Independent Chairman of the Board

Dr. Alan William Dunton, M.D.

Independent Director

Ms. Elizabeth (Liz) Massonhurlburt

Chief Operating Officer

Dr. Matthew T. (Matt) David, M.D.

Chief Business Officer

名稱

名稱/職務

職務

持股

持股變動

Mr. Joseph (Joe) Todisco

Chief Executive Officer, Director

302.20K

Mr. Steven W. Lefkowitz

Independent Director

87.65K

-40000.00%

Ms. Susan Blum

Chief Financial Officer

69.69K

+69686.00%

Ms. Janet M. Dillione

Independent Director

23.47K

Mr. Gregory Scott (Greg) Duncan

Independent Director

13.33K

+13333.00%

Mr. Robert Stewart

Independent Director

11.00K

收入明細

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

104.28M

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

6.40%

Deep Track Capital LP

6.29%

Abdalkader (Shaibatalhamd Aymen)

5.84%

The Vanguard Group, Inc.

5.03%

Marshall Wace LLP

4.41%

其他

72.03%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

6.40%

Deep Track Capital LP

6.29%

Abdalkader (Shaibatalhamd Aymen)

5.84%

The Vanguard Group, Inc.

5.03%

Marshall Wace LLP

4.41%

其他

72.03%

股東類型

持股股東

佔比

Investment Advisor

26.64%

Hedge Fund

16.79%

Investment Advisor/Hedge Fund

15.24%

Individual Investor

6.94%

Research Firm

2.04%

Pension Fund

1.09%

Bank and Trust

0.33%

Insurance Company

0.03%

Venture Capital

0.03%

其他

30.87%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

345

48.63M

61.72%

+3.95M

2025Q3

340

43.85M

56.33%

+8.67M

2025Q2

304

34.76M

43.08%

+9.67M

2025Q1

267

24.95M

43.35%

-4.41M

2024Q4

241

23.99M

39.87%

+4.76M

2024Q3

216

19.17M

36.31%

+1.94M

2024Q2

207

17.23M

38.40%

-272.84K

2024Q1

207

17.37M

41.54%

-5.46M

2023Q4

207

18.82M

39.64%

+838.41K

2023Q3

199

17.96M

39.30%

-1.31M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

5.04M

6.4%

+248.22K

+5.18%

Sep 30, 2025

Deep Track Capital LP

4.96M

6.29%

+4.46M

+891.10%

Nov 21, 2025

Abdalkader (Shaibatalhamd Aymen)

4.65M

6.22%

+4.65M

Aug 08, 2025

The Vanguard Group, Inc.

3.96M

5.03%

-347.89K

-8.07%

Sep 30, 2025

Marshall Wace LLP

3.47M

4.41%

+893.52K

+34.63%

Sep 30, 2025

Deerfield Management Company, L.P.

3.32M

4.22%

+3.32M

Sep 30, 2025

State Street Investment Management (US)

1.84M

2.33%

+233.97K

+14.61%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.81M

2.3%

+213.45K

+13.37%

Sep 30, 2025

Citadel Advisors LLC

1.72M

2.18%

+2.87K

+0.17%

Sep 30, 2025

Alyeska Investment Group, L.P.

1.26M

1.6%

+512.98K

+68.40%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

State Street SPDR S&P Pharmaceuticals ETF

2.01%

Invesco Biotechnology & Genome ETF

1.87%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.52%

VictoryShares Small Cap Free Cash Flow ETF

0.79%

First Trust Active Factor Small Cap ETF

0.3%

Janus Henderson Small Cap Growth Alpha ETF

0.25%

ALPS Barron's 400 ETF

0.21%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.19%

Vanguard US Multifactor ETF

0.16%

iShares Micro-Cap ETF

0.15%

State Street SPDR S&P Pharmaceuticals ETF

佔比2.01%

Invesco Biotechnology & Genome ETF

佔比1.87%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.52%

VictoryShares Small Cap Free Cash Flow ETF

佔比0.79%

First Trust Active Factor Small Cap ETF

佔比0.3%

Janus Henderson Small Cap Growth Alpha ETF

佔比0.25%

ALPS Barron's 400 ETF

佔比0.21%

Janus Henderson Small/Mid Cap Growth Alpha ETF

佔比0.19%

Vanguard US Multifactor ETF

佔比0.16%

iShares Micro-Cap ETF

佔比0.15%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據

常見問題

CorMedix Inc的前五大股東是誰？



CorMedix Inc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：5.04M
佔總股份比例：6.40%。
Deep Track Capital LP
持有股份：4.96M
佔總股份比例：6.29%。
Abdalkader (Shaibatalhamd Aymen)
持有股份：4.65M
佔總股份比例：6.22%。
The Vanguard Group, Inc.
持有股份：3.96M
佔總股份比例：5.03%。
Marshall Wace LLP
持有股份：3.47M
佔總股份比例：4.41%。